Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Recruiting · Phase 1 · NCT02013336
Conditions: Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
At a glance
- Research payments reported, 2025
- $59,780
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- South Plains Oncology Consortium
- Tested
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide (drug)
- Dates
- Started 2013-12; completion 2027-03
- Results posted
- Not yet
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
From ClinicalTrials.gov, last updated 2026-10-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $59,780 in research payments for this study in 2025 (1 payments).
Products named: Onivyde
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Tech University Health Sciences Center School of Medicine $59,780
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.